BackCarisma Therapeutics Overview

Carisma Therapeutics Total Revenue

Latest total revenue for CARM: $3.7M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Sep 2025

Annual Revenue (TTM)

$3.65M
81.98% YoY

Trailing 12 months ending Sep 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Carisma Therapeutics (CARM) FAQ

The latest total revenue for CARM is $3.7M as of September 2025. That compares with $20M in the prior-year period — down 82.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Carisma Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CARM's total revenue moved from $20M to $3.7M — a 82.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Carisma Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CARM currently prints $3.7M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Carisma Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $3.7M for CARM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CARM's total revenue ($3.7M), review year-over-year change from $20M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.